Brief: Arovella Therapeutics Says Research And Development Facility Closure Reduces costs by A$1.5M Per Annum
01/05/2023 02:19
May 1 (Reuters) - Arovella Therapeutics ALA.AX :
* PERTH-BASED RESEARCH AND DEVELOPMENT FACILITY CLOSURE
REDUCES
EXPENDITURE BY APPROXIMATELY A$1.5M PER ANNUM
Source text for Eikon: ID:nASXl2YhQ
Further company coverage: ALA.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arovella Therapeutics
See all newsBrief: Arovella Therapeutics Appoints Acting CEO
Brief: Arovella Therapeutics Says Michael Baker Resigns As CEO
Brief: Arovella Therapeutics Says Elizabeth Stoner Will Be Retiring As Interim Chair
Brief: Arovella Therapeutics Says IND For Ala-101 Accepted By FDA
Brief: Arovella Therapeutics Appoints Lachie Mallia As CFO